Immunotherapy makes breakthrough in breast cancer

Global study shows immunotherapy, combined with chemotherapy, can help to extend lives of patients with aggressive breast cancer

In the Impassion 130 study, triple-negative breast cancer patients treated with immunotherapy and chemotherapy survived 7.2 months without the disease progressing, compared with 5.5 months in the chemotherapy- only group.
In the Impassion 130 study, triple-negative breast cancer patients treated with immunotherapy and chemotherapy survived 7.2 months without the disease progressing, compared with 5.5 months in the chemotherapy- only group.PHOTO: ISTOCKPHOTO
  • Published
    Nov 5, 2018, 5:00 am SGT
New: Gift this subscriber-only story to your friends and family

News that combining chemotherapy with immunotherapy can help extend the lifespan of triple-negative breast cancer patients offers hope for those inflicted with this aggressive and hard-to-treat cancer.

It is a breakthrough for immunotherapy as breast cancer was thought to be unresponsive to the body's immune system.

Please or to continue reading the full article.

Get unlimited access to all stories at $0.99/month

  • Latest headlines and exclusive stories
  • In-depth analyses and award-winning multimedia content
  • Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*
Subscribe now

*Terms and conditions apply.

Join ST's Telegram channel here and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Straits Times on November 05, 2018, with the headline 'Immunotherapy makes breakthrough in breast cancer'. Subscribe
Topics: